CABG, PTCA or medical management? for Coronary artery disease
Publication
, Journal Article
Hochrein, J; Mark, DB
Published in: Primary Cardiology
January 1, 1995
The use of percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass grafting (CABG), or medical therapy for treatment of coronary artery disease (CAD) continues to be evaluated in randomized clinical trials and through review of treatment outcomes from cardiovascular patient registries, such as the Duke Cardiovascular Disease Databank. Early revascularization with CABG appears to improve survival in those patients with the most severe forms of CAD and the highest risk for cardiovascular events. However, for patients with less severe forms of CAD, PTCA or medical management may be the optimal therapy. Choice of treatment strategy must be made after careful consideration of many clinical and angiographic factors.
Duke Scholars
Published In
Primary Cardiology
ISSN
0363-5104
Publication Date
January 1, 1995
Volume
21
Issue
8
Start / End Page
21 / 25
Citation
APA
Chicago
ICMJE
MLA
NLM
Hochrein, J., & Mark, D. B. (1995). CABG, PTCA or medical management? for Coronary artery disease. Primary Cardiology, 21(8), 21–25.
Hochrein, J., and D. B. Mark. “CABG, PTCA or medical management? for Coronary artery disease.” Primary Cardiology 21, no. 8 (January 1, 1995): 21–25.
Hochrein J, Mark DB. CABG, PTCA or medical management? for Coronary artery disease. Primary Cardiology. 1995 Jan 1;21(8):21–5.
Hochrein, J., and D. B. Mark. “CABG, PTCA or medical management? for Coronary artery disease.” Primary Cardiology, vol. 21, no. 8, Jan. 1995, pp. 21–25.
Hochrein J, Mark DB. CABG, PTCA or medical management? for Coronary artery disease. Primary Cardiology. 1995 Jan 1;21(8):21–25.
Published In
Primary Cardiology
ISSN
0363-5104
Publication Date
January 1, 1995
Volume
21
Issue
8
Start / End Page
21 / 25